Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Leukemia |
Free Subscription
5 Am J Hematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Characteristics and outcomes of patients with relapsed Philadelphia
chromosome-positive acute lymphoblastic leukemia after failure of a frontline
ponatinib-containing therapy.
Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
PubMed
World Health Organization and International Consensus Classification of
eosinophilic disorders: 2024 update on diagnosis, risk stratification, and
management.
Am J Hematol. 2024;99:946-968.
PubMed
Abstract available
Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells
for patients with multiply relapsed and refractory AML.
Am J Hematol. 2024;99:890-899.
PubMed
Abstract available
Relative prognostic value of flow cytometric measurable residual disease before
allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
Am J Hematol. 2024;99:862-870.
PubMed
Abstract available
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete
molecular remission.
Am J Hematol. 2024;99:806-815.
PubMed
Abstract available
Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute
lymphoblastic leukemia/lymphoma in first complete remission: a single-center
study.
Ann Hematol. 2024 Apr 12. doi: 10.1007/s00277-024-05716.
PubMed
Abstract available
Efficacy and prognostic factors of allogeneic hematopoietic stem cell
transplantation treatment for adolescent and adult Tlymphoblastic leukemia
/lymphoma: a large cohort multicenter study in China.
Ann Hematol. 2024 Apr 6. doi: 10.1007/s00277-024-05719.
PubMed
Abstract available
Making AML fly too close to the sun.
Blood. 2024;143:1438-1439.
PubMed
Mezigdomide is effective alone and in combination with menin inhibition in
preclinical models of KMT2A-r and NPM1c AML.
Blood. 2024;143:1513-1527.
PubMed
Abstract available
EASIX and CPSS Cytogenetics score-based composite risk model for patients with
CMML undergoing allogeneic transplant.
Bone Marrow Transplant. 2024;59:558-560.
PubMed
Outcomes of haploidentical bone marrow transplantation in infant acute leukemia:
a single center experience.
Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
PubMed
Early clearance of hairy cell leukaemia in the bone marrow after first-line
treatment with cladribine predicts a favourable outcome.
Br J Haematol. 2024;204:1288-1292.
PubMed
Abstract available
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH
inhibitors.
Br J Haematol. 2024;204:1238-1242.
PubMed
Abstract available
Treatment and follow-up of children with chronic myeloid leukaemia in chronic
phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of
experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Br J Haematol. 2024;204:1249-1261.
PubMed
Abstract available
Venetoclax and hypomethylating agents in critically ill patients with newly
diagnosed acute myeloid leukaemia.
Br J Haematol. 2024;204:1219-1226.
PubMed
Abstract available
Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed
acute myeloid leukaemia requiring admission to the intensive care unit: Possible
reduction in side effects with preserved efficacy.
Br J Haematol. 2024;204:1135-1136.
PubMed
Abstract available
Quantitative computed tomography analysis of body composition changes in
paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1335-1343.
PubMed
Abstract available
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin
D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:1227-1231.
PubMed
Abstract available
Venetoclax resistance in acute myeloid leukaemia-Clinical and biological
insights.
Br J Haematol. 2024;204:1146-1158.
PubMed
Abstract available
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with
venetoclax + hypomethylating agents.
Br J Haematol. 2024;204:1232-1237.
PubMed
Abstract available
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in
chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024;204:1536-1539.
PubMed
Risk factors and survival analysis of human leukocyte antigen loss in relapsed
acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic
haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:1402-1413.
PubMed
Abstract available
The heart of VIALE-A: Cardiac complications of hypomethylating agents and
venetoclax in acute myeloid leukaemia.
Br J Haematol. 2024;204:1137-1138.
PubMed
Abstract available
The Mozart effect in chronic myeloid leukaemia.
Br J Haematol. 2024;204:1139-1140.
PubMed
Abstract available
Validation of the Artificial Intelligence Prognostic Scoring System for
Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach
for improved risk stratification.
Br J Haematol. 2024;204:1529-1535.
PubMed
Abstract available
High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric
acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Br J Haematol. 2024;204:1354-1366.
PubMed
Abstract available
Relevance of CD20 antigen expression among paediatric patients with B-lineage
acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1367-1374.
PubMed
Abstract available
Refining risk stratification in paediatric B-acute lymphoblastic leukaemia:
Combining IKZF1(plus) and Day 15 MRD positivity.
Br J Haematol. 2024;204:1344-1353.
PubMed
Abstract available
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic
myeloid leukemia.
Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
PubMed
Abstract available
Prognostic impact of number of induction courses to attain complete remission in
patients with acute myeloid leukemia transplanted with either a matched sibling
or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia
Working Party
Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
PubMed
Abstract available
TP53 in MDS and AML: Biological and clinical advances.
Cancer Lett. 2024;588:216767.
PubMed
Abstract available
ATPR induces acute promyelocytic leukemia cells differentiation and cycle arrest
via the lncRNA CONCR/DDX11/PML-RARalpha signaling axis.
Gene. 2024 Apr 4:148443. doi: 10.1016/j.gene.2024.148443.
PubMed
Abstract available
Changes in chronic myeloid leukemia treatment modalities and outcomes after
introduction of second-generation tyrosine kinase inhibitors as first-line
therapy: a multi-institutional retrospective study by the CML Cooperative Study
Group.
Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
PubMed
Abstract available
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment
of relapsed/refractory hairy cell leukemia, a multicenter experience.
Leuk Res. 2024;140:107495.
PubMed
Abstract available
Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid
leukemia: A subgroup based meta-analysis.
Leuk Res. 2024;140:107498.
PubMed
Abstract available
Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic
strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
PubMed
Abstract available
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
PubMed
Abstract available
Allogeneic haematopoietic cell transplantation for advanced systemic
mastocytosis: Best practice recommendations on behalf of the EBMT Practice
Harmonisation and Guidelines Committee.
Leukemia. 2024;38:699-711.
PubMed
Abstract available
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis:
A retrospective analysis of the DRST and GREM registries.
Leukemia. 2024;38:810-821.
PubMed
Abstract available
Hypomethylating agents plus venetoclax compared with intensive induction
chemotherapy regimens in molecularly defined secondary AML.
Leukemia. 2024;38:762-768.
PubMed
Abstract available
Clinical impact of genetic alterations including germline DDX41 mutations in
MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia. 2024;38:918-922.
PubMed
Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel
clusters and divergent ex-vivo drug responses.
Leukemia. 2024;38:751-761.
PubMed
Abstract available
Deletion of the TMEM30A gene enables leukemic cell evasion of NK cell
cytotoxicity.
Proc Natl Acad Sci U S A. 2024;121:e2316447121.
PubMed
Abstract available
Thank you for your interest in scientific medicine.